Literature DB >> 21389791

Therapy options in irritable bowel syndrome.

Paul Enck1, Florian Junne, Sibylle Klosterhalfen, Stephan Zipfel, Ute Martens.   

Abstract

BACKGROUND: Numerous meta-analyses have recently assessed the overall clinical benefit of single therapy options and groups of therapies in the irritable bowel syndrome (IBS). By large, this should enable physicians to select from a number of therapy options available.
METHODS: We entered dichotomous outcome data from 121 IBS trials published over the last 35 years with different groups and subgroups of drugs (antispasmodics, motility-affecting agents, antidepressants, peppermint oil), dietary interventions (bran, probiotics), and psychotherapy (cognitive behavioral, psychodynamic, hypnotherapy, relaxation techniques) into meta-analytic tools and estimate the overall efficacy (odds ratio, number needed to treat).
RESULTS: Highest efficacy is currently found for peppermint oil, followed by psychotherapeutic and psychopharmacological interventions and probiotics. Traditional antispasmodic therapy has a moderate efficacy, whereas the list of (partially failed or cancelled) motility affecting drugs yielded weak clinical results, and therapies by bran and fibers are of no value in IBS.
CONCLUSION: Evidence-based therapy in IBS provides a number of effective treatment options beyond the fact that many novel compounds under development have failed to reach the market. An algorithm for clinical therapy decision is proposed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21389791     DOI: 10.1097/MEG.0b013e3283405a17

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  21 in total

1.  Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

Authors:  Peter Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-04       Impact factor: 3.000

Review 2.  [Visceral pain].

Authors:  S Elsenbruch; W Häuser; W Jänig
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

Review 3.  [Placebo response: in studies on pain and under other clinical conditions].

Authors:  K Weimer; B Horing; S Klosterhalfen; P Enck
Journal:  Schmerz       Date:  2011-06       Impact factor: 1.107

Review 4.  The placebo response in clinical trials: more questions than answers.

Authors:  Paul Enck; Sibylle Klosterhalfen; Katja Weimer; Björn Horing; Stephan Zipfel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

Review 5.  Brain-gut microbiome interactions and functional bowel disorders.

Authors:  Emeran A Mayer; Tor Savidge; Robert J Shulman
Journal:  Gastroenterology       Date:  2014-02-28       Impact factor: 22.682

6.  Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study.

Authors:  Jin Young Yoon; Jae Myung Cha; Ju Kyoung Oh; Pei Lei Tan; Sae Hun Kim; Min Seob Kwak; Jung Won Jeon; Hyun Phil Shin
Journal:  Dig Dis Sci       Date:  2018-06-07       Impact factor: 3.199

Review 7.  The Efficacy, Safety and Applications of Medical Hypnosis.

Authors:  Winfried Häuser; Maria Hagl; Albrecht Schmierer; Ernil Hansen
Journal:  Dtsch Arztebl Int       Date:  2016-04-29       Impact factor: 5.594

8.  Changes in gut microbial metagenomic pathways associated with clinical outcomes after the elimination of malabsorbed sugars in an IBS cohort.

Authors:  A Mack; J S Bobardt; A Haß; K B Nichols; R M Schmid; C K Stein-Thoeringer
Journal:  Gut Microbes       Date:  2019-12-06

9.  The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses.

Authors:  Stefan G Hofmann; Anu Asnaani; Imke J J Vonk; Alice T Sawyer; Angela Fang
Journal:  Cognit Ther Res       Date:  2012-07-31

10.  Efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety.

Authors:  Ling Lan; Yu-Long Chen; Hao Zhang; Bai-Ling Jia; Yan-Jun Chu; Jin Wang; Shi-Xiao Tang; Guo-Dong Xia
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.